Browse by Vaccine Status

This page shows data for Phase 2 Vaccine Status.
Total Entries Retrieved: 74
IDVaccine NameDisease NameDisease ClassificationVirus NameNucleic Acid ContentVaccine TypeVaccine StatusManufacturerYear of ManufacturingManufacturing CountryAgeDosageAdministration RouteAdjuvantTarget StrainDescriptionApproving OrganisationCollaborating OrganisationOther CountriesTrade NamePMIDClinical Trial IDReference LinkAdditional Links
10239 QazCoVac-P COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Protein subunit Phase 2 Research Institute for Biological Safety Problems 2021 Kazakhstan 18 years and above 2 doses 21 days apart Intramuscular Aluminum Spike protein of SARS-CoV-2 virus NA NA NA NA NA NA NCT04930003 https://clinicaltrials.gov/show/NCT04930003 NA
10240 RBD-HBsAg VLP COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Virus like particle Phase 2 Serum Institute of India, Accelagen Pty 2021 Australia 18 - 79 years 2 doses 28 days apart Intramuscular CpG 1018, alum SARS-CoV-2 receptor-binding domain from spike protein NA NA NA NA NA NA NA https://anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=12620001308987 NA
10241 S-268019 COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Protein subunit Phase 2 Shionogi Inc. 2021 Japan 20 - 64 years NA Intramuscular NA NA NA NA NA NA NA NA NA https://jrct.niph.go.jp/en-latest-detail/jRCT2051200092 NA
10242 V-01 COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Protein subunit Phase 2 Livzon Mabpharm Inc. 2021 China 18 years and above 2 doses 28 days apart Intramuscular NA Recombinant SARS-CoV-2 fusion protein NA NA NA NA NA NA NA http://www.chictr.org.cn/showproj.aspx?proj=124702 NA
10243 VLA2001 Inactivated SARS-CoV-2 vaccine (Vero cell) COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Inactivated Phase 2 Valneva 2020 Austria 18 - 55 years 2 doses 21 days apart Intramuscular CpG 1018, aluminium hydroxide NA NA NA NA NA NA NA NCT04671017 https://clinicaltrials.gov/show/NCT04671017 NA
10244 HGCO19 (COVID-19 vaccine) COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA RNA based vaccine Phase 2 Gennova Biopharmaceuticals Limited 2020 India 18 years and above NA Intramuscular NA Spike protein of SARS-CoV-2 virus mRNA based vaccine NA HDT Biotech Corporation NA HGCO19 (COVID-19 vaccine) NA NA https://gennova.bio/mrna-vaccines/ https://vaccine.icmr.org.in/covid-19-vaccine
10245 SpikoGen COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Protein subunit Phase 2 CinnaGen Company 2021 Iran 18 years and above 2 doses 21 days apart Intramuscular Advax-CpG Spike protein of SARS-CoV-2 virus NA NA NA NA NA NA NA http://en.irct.ir/trial/56287 NA
10246 SII B.1.617.2 COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Protein subunit Phase 2 Novavax Inc. 2021 Australia 18 - 64 years 2 doses 21 days apart Intramuscular Matrix-M1 Bivalent SII vaccine containing antigen for both the ancestral strain and B.1.351 (Beta) variant of SARS-CoV-2 (SII Bivalent) NA NA NA NA NA NA NCT05029856 https://clinicaltrials.gov/ct2/show/NCT05029856 NA
10247 SCB-2020S COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Protein subunit Phase 2 Clover Biopharmaceuticals 2021 Australia 18 - 75 years 2 doses 22 days apart Intramuscular AS03, CpG 1018, alum SARS-CoV-2(B.1.351 variant) trimeric spike protein NA NA NA NA NA NA NCT04950751 https://www.clinicaltrials.gov/ct2/show/NCT04950751 NA
10248 EXG-5003 COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA RNA based vaccine Phase 2 Elixirgen Therapeutics Inc. 2021 Japan 20 - 55 years NA Intradermal NA NA mRNA based vaccine NA NA NA NA NA NCT04863131 https://clinicaltrials.gov/show/NCT04863131 NA
10249 BNT162a1 COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA RNA based vaccine Phase 2 BioNTech SE, Pfizer Inc. NA NA NA NA Intramuscular NA SARS-CoV-2 spike protein mRNA encapsulated in a lipid nanoparticle NA NA NA NA BNT162b1, BNT162b2, BNT162c2 32585611 NA https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7301105/ NA
10250 COVID-19 Vaccine Nasal Spray COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Recombinant viral vector Phase 2 Xiamen University 2021 China 18 years and above 2 doses 14 days apart Intranasal NA NA NA NA University of Hong Kong, Beijing Wantai Biological Pharmacy NA NA 33937326 NA https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8082173/ NA
10251 hAd5-COVID-19 COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Recombinant viral vector Phase 2 ImmunityBio Inc. 2021 USA 18 - 80 years NA Subcutaneous NA Spike & Nucleocapsid protein NA NA NA NA NA 33937326 NCT04843722 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8082173/ NA
10252 DS-5670a COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA RNA based vaccine Phase 2 Daiichi Sankyo Co. Ltd. 2021 Japan 20 - 74 years 2 doses Intramuscular NA NA mRNA based vaccine NA NA NA NA NA NCT04821674 https://clinicaltrials.gov/ct2/show/NCT04821674 NA
10253 ZyCoV-D COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA DNA based vaccine Phase 2 Cadila Healthcare Ltd NA NA NA 3 doses on day 0, 28 and 56 Intradermal NA NA NA NA NA NA nCov vaccine 33816047 NA https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8003899/ NA
10254 GX-19 COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA DNA based vaccine Phase 2 Genexine Consortium 2021 South Korea 18 - 55 years 2 doses 28 days apart Intramuscular NA SARS-CoV-2 S-protein antigen including the Nucleocapsid protein antigen NA NA NA NA NA 33816047 NCT04715997 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8003899/ NA
10255 KBP-COVID-19 COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Protein subunit Phase 2 Kentucky Bioprocessing Inc 2021 USA 18 - 85 years 2 doses 21 days apart Intramuscular CpG 1018 SARS-CoV-2 receptor-binding domain from spike protein NA US FDA NA NA NA 33816047 NCT04473690 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8003899/ NA
10256 KD-414 COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Inactivated Phase 2 KM Biologics Co. Ltd. 2021 Japan 20 years and above 2 doses 27 days apart Intramuscular NA NA NA NA NA NA NA NA NA https://jrct.niph.go.jp/en-latest-detail/jRCT2071200106 NA
10257 Vidprevtyn COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Protein subunit Phase 2 Sanofi Pasteur, GlaxoSmithKline NA NA NA 2 doses 21 days apart Intramuscular NA Spike protein of SARS-CoV-2 virus Baculovirus production NA NA NA VAT00002, VAT00008, SARS-CoV-2 vaccine 33816047 NA https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8003899/ NA
10258 LUNAR-COV19 COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA RNA based vaccine Phase 2 Arcturus Therapeutics 2021 Singapore NA 2 doses 28 days apart Intramuscular NA Self-replicating RNA mRNA based vaccine NA NA NA SARS-CoV-2 vaccine, ARCT-021 33816047 NCT05037097 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8003899/ NA
10259 RBD SARS-CoV-2 HBsAg VLP vaccine COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Virus like particle Phase 2 Serum Institute of India, Accelagen Pty NA NA NA 2 doses 28 days apart Intramuscular NA NA NA NA NA NA NA 33816047 NA https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8003899/ NA
10260 AV-COVID-19 COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Recombinant viral vector Phase 2 Aivita Biomedical Inc. 2021 USA 18 years and above Single dose Intramuscular GM-CSF Spike protein of SARS-CoV-2 virus NA US FDA NA NA NA 33816047 NCT05007496 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8003899/ https://clinicaltrials.gov/ct2/show/NCT05007496
10261 MVA-SARS-2-S COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Recombinant viral vector Phase 2 City of Hope Medical Center, National Cancer Institute 2021 USA 18 years and above 2 doses 28 days apart Intramuscular NA Spike protein of SARS-CoV-2 virus NA US FDA NA NA COH04S1 33816047 NCT04977024 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8003899/ NA
10262 hAd5-COVID-19 COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Recombinant viral vector Phase 2 ImmunityBio Inc. 2021 USA 18 - 80 years Single dose Subcutaneous NA Spike & nucleocapsid protein of SARS-CoV-2 virus NA US FDA NA NA NA 33816047 NCT04843722 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8003899/ NA
10263 LV-SMENP-DC COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Virus like particle Phase 2 Shenzhen Geno-Immune Medical Institute NA NA NA Single dose Subcutaneous, Intravenous NA NA NA NA NA NA NA 33816047 NA https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8003899/ NA
10264 DelNS1-2019-nCoV-RBD-OPT1 COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Replicating viral vector Phase 2 Beijing Wantai Biological NA NA NA Single dose Intranasal NA NA NA NA Jiangsu Province Centers for Disease Control and Prevention NA NA 33816047 NCT04809389 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8003899/ https://clinicaltrials.gov/ct2/show/NCT04809389
10265 TMV-o38 COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Replicating viral vector Phase 2 Merck & Co. Inc. NA NA NA 2 doses 28 days apart Intramuscular NA NA NA NA Themis, Sharp & Dohme, Institute Pasteur, Univeristy of Pittsburgh NA V591-001—Measles-vector based 33816047 NA https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8003899/ NA
10266 Recombinant COVID-19 Vaccine (CHO cell, NVSI-06-08) COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Protein subunit Phase 2 National Vaccine and Serum Institute 2021 China 3 years and above NA Intramuscular NA NA NA NA NA NA NA NA NCT04869592 https://clinicaltrials.gov/ct2/show/NCT05069129 NA
10267 PHH-1V COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Protein subunit Phase 2 Laboratorios HIPRA SA 2021 Spain 18 - 39 years 2 doses 21 days apart Intramuscular NA Spike protein of SARS-CoV-2 virus NA NA NA NA COVID-19 subunit vaccine NA NCT05007509 https://www.clinicaltrialsregister.eu/ctr-search/trial/2022-000074-25/ES NA
10268 COVAC COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Protein subunit Phase 2 Vaccine and Infectious Disease Organization 2021 Canada 18 years and above 2 doses 28 days apart Intramuscular SWE Spike protein of SARS-CoV-2 virus NA NA Vaccine Formulation Institute NA NA NA NCT04702178 https://clinicaltrials.gov/ct2/show/NCT04702178 NA
10269 CoVac-1 COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Protein subunit Phase 2 University Hospital Tuebingen 2021 Germany 18 years and above Single dose Subcutaneous NA SARS-CoV-2 HLA-DR peptides NA NA NA NA IMP 33816047 NCT04954469 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8003899/ NA
10270 COVID-19 VLP vaccine COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Virus like particle Phase 2 The Scientific and Technological Research Council of Turkey 2021 Turkey 18 - 59 years 2 doses 21 days apart Subcutaneous Alum adsorbed, CpG ODN Spike protein of SARS-CoV-2 virus NA NA NA NA NA NA NCT04962893 https://clinicaltrials.gov/ct2/show/NCT04962893 NA
10271 Pasteur COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Protein subunit Phase 2 Instituto Finlay de Vacunas 2021 Cuba NA 2 doses 28 days apart Intramuscular NA Spike protein of SARS-CoV-2 virus NA NA NA NA FINLAY-FR-2, Pasteurcovac, Pasto Covac, Soberana 02, Soberana 2 33816047 NA https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8003899/ NA
10272 MF59 adjuvanted SARS-CoV-2 Sclamp vaccine COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Protein subunit Phase 2 University of Queensland 2021 Australia 18 years and above 2 doses 28 days apart Intramuscular MF59 Spike protein of SARS-CoV-2 virus NA NA NA NA SARS-CoV-2 Sclamp 33816047 NCT04495933 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8003899/ NA
10273 Comirnaty COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA RNA based vaccine Phase 2 BioNTech SE, Pfizer Inc. 2020 NA 18 - 55 years 2 doses 21 days apart Intramuscular NA Spike protein of SARS-CoV-2 virus mRNA based vaccine US FDA NA NA BNT162b2, COVID-19 mRNA vaccine 33402220 NCT04368728 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7785400/ https://clinicaltrials.gov/ct2/show/NCT04368728
10274 COVID-eVax COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA DNA based vaccine Phase 2 Takis, Rottapharm Biotech 2021 Italy 18 - 65 years 2 doses 4 weeks apart Intramuscular NA Spike protein of SARS-CoV-2 virus NA NA NA NA NA NA NCT04788459 https://clinicaltrials.gov/show/NCT04788459 NA
10275 ABNCoV2 COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Virus like particle Phase 2 Radboud University 2021 Netherlands 18 - 55 years 2 doses 14 days apart Intramuscular MF59 NA NA NA NA NA NA NA NCT04839146 https://clinicaltrials.gov/ct2/show/NCT04839146 NA
10276 EuCorVac-19 COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Protein subunit Phase 2 EuBiologics Co. Ltd. 2021 South Korea 19 - 75 years 2 doses 3 weeks apart Intramuscular NA NA NA NA NA NA NA NA NCT04783311 https://clinicaltrials.gov/show/NCT04783311 NA
10277 VBI-2902a COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Virus like particle Phase 2 VBI Vaccines Inc. 2021 Canada 18 years and above 2 doses 28 days apart Intramuscular Aluminum (aluminum phosphate) Spike protein of SARS-CoV-2 virus NA NA NA NA NA NA NCT04773665 https://clinicaltrials.gov/show/NCT04773665 NA
10278 UB-612 COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Protein subunit Phase 2 United Biomedical Inc. 2021 China 12 - 85 years 2 doses Intramuscular NA NA NA NA NA NA NA NA NCT04773067 https://clinicaltrials.gov/show/NCT04773067 https://clinicaltrials.gov/ct2/show/NCT04683224
10279 COVIVAC COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Recombinant viral vector Phase 2 Icahn School of Medicine, Mahidol University 2021 Thailand 18 - 75 years 2 doses 28 days apart Intramuscular CpG 1018 Spike protein of SARS-CoV-2 virus NA NA NA NA ADAPTCOV, NDV-HXP-S vaccine, , HXP-GPOVac, Patria, ButanVac NA NCT04764422 https://clinicaltrials.gov/show/NCT04764422 NA
10280 AV-COVID-19 COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Non-replicating viral vector Phase 2 Aivita Biomedical Inc. 2020 USA 18 years and above NA Intranasal GM-CSF Spike protein of SARS-CoV-2 virus NA US FDA NA NA NA NA NCT05007496 https://clinicaltrials.gov/show/NCT04386252 https://clinicaltrials.gov/ct2/show/NCT05007496
10281 AKS-452 COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Protein subunit Phase 2 University Medical Center Groningen 2021 Netherlands 18 - 65 years NA Subcutaneous NA SARS-CoV-2 receptor-binding domain from spike protein NA NA NA NA NA NA NCT04681092 https://clinicaltrials.gov/show/NCT04681092 NA
10282 GLS-5310 COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA DNA based vaccine Phase 2 GeneOne Life Science Inc. 2021 South Korea 19 - 65 years 2 doses 28 days apart Intradermal NA NA NA NA NA NA NA NA NCT04673149 https://clinicaltrials.gov/show/NCT04673149 NA
10283 MRT5500 COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA RNA based vaccine Phase 2 Sanofi Pasteur, Translate Bio 2021 USA 18 years and above 2 doses 28 days apart Intramuscular NA NA mRNA based vaccine US FDA NA NA VAW00001 NA NCT04847050 https://www.clinicaltrials.gov/ct2/show/NCT04847050 NA
10284 MVA-SARS-2-ST COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Recombinant viral vector Phase 2 German Center for Infection Research 2021 Germany 18 years and above 2 doses 28 days apart Intramuscular NA Modified Vaccinia Virus Ankara vector expressing a stabilized SARS-CoV-2 spike protein NA NA NA NA NA NA NCT04895449 https://clinicaltrials.gov/ct2/show/NCT04895449 NA
10285 LV-SMENP COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Non-replicating viral vector Phase 2 Shenzhen Geno-Immune Medical Institute 2021 China 6 months and above NA Subcutaneous NA Covid-19 minigene SMENP and immune modulatory genes NA NA NA NA NA NA NCT04276896 https://clinicaltrials.gov/show/NCT04276896 NA
10286 V-SARS COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Plasma based Phase 2 Immunitor LLC 2020 Canada 18 - 65 years NA Oral NA Pooled plasma of COVID-19 patients NA NA NA NA NA NA NCT04380532 https://clinicaltrials.gov/show/NCT04380532 NA
10287 QazVac COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Inactivated Phase 2 Research Institute for Biological Safety Problems 2020 Kazakhstan 18 years and above 2 doses 21 days apart Intramuscular NA NA NA NA NA NA QazCovid-in NA NCT04530357 https://clinicaltrials.gov/show/NCT04530357 NA
10288 ZR-202-CoV COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Protein subunit Phase 2 Shanghai Zerun Biotechnology, Walvax Biotechnology, CEPI 2021 China 18 years and above 2 doses 28 days apart Intramuscular CpG, alum SARS-CoV-2 protein NA NA NA NA NA NA NCT04990544 https://clinicaltrials.gov/ct2/show/NCT05313022 NA
10289 AG0302-COVID19 COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA DNA based vaccine Phase 2 AnGes Inc. 2021 Japan 18 years and above 3 doses 2 weeks apart Intramuscular NA Spike protein of SARS-CoV-2 virus NA NA NA NA NA NA NCT04993586 https://clinicaltrials.gov/ct2/show/NCT04993586 NA
10290 AAV5-RBD-S COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Recombinant viral vector Phase 2 Biocad 2021 Russia 18 - 60 years NA Intramuscular NA SARS-CoV-2 receptor-binding domain from spike protein NA NA NA NA NA NA NCT05037188 https://clinicaltrials.gov/ct2/show/NCT05037188 NA
10291 AdCLD-CoV19 COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Recombinant viral vector Phase 2 Cellid Co. Ltd. 2021 South Korea 19 - 64 years Single dose Intramuscular NA Spike protein of SARS-CoV-2 virus NA NA NA NA NA NA NCT04666012 https://clinicaltrials.gov/ct2/show/NCT04666012 NA
10292 BVRS-GamVac MERS Respiratory MERS-CoV positive-sense, single-stranded RNA Non-replicating viral vector Phase 2 Gamaleya Research Institute of Epidemiology and Microbiology 2021 Russia 18 - 55 years NA Intramuscular NA MERS CoV spike glycoprotein NA NA Health Ministry of the Russian Federation NA NA NA NCT04130594 https://clinicaltrials.gov/ct2/show/NCT04130594?cond=MERS-CoV&phase=0123&draw=2&rank=14 NA
10293 GLS-5300 (INO-4700) MERS Respiratory MERS-CoV positive-sense, single-stranded RNA DNA based vaccine Phase 2 GeneOne Life Science Inc. 2020 South Korea 19 - 70 years 3 doses Intradermal NA MERS CoV spike glycoprotein NA NA Inovio Pharmaceuticals, International Vaccine Institute NA GLS-5300 NA NCT03721718 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7749790/ NA
10294 cAd3-EBO Ebola Hemorrhagic Zaire ebolavirus negative-sense, single-stranded RNA Recombinant viral vector Phase 2 Centre Hospitalier Universitaire Vaudois 2014 Switzerland 18 - 65 years NA Intramuscular NA Zaire Ebola virus glycoprotein Chimpanzee Adenovirus Vector expressing Zaire strain glycoprotein NA NA NA NA 27764560 NCT02289027 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5287303/ NA
10295 DSV4 Dengue fever Hemorrhagic Dengue virus positive-sense, single-stranded RNA Subunit vaccine Phase 2 Panacea Biotec Ltd NA India 2 - 60 years NA NA NA Chimeric protein containing vHBsAg,DS, unique tetravalent dengue antigen Produced using the methylotrophic yeast Pichia pastoris NA NA NA NA 30684747 NA https://www.sciencedirect.com/science/article/pii/S1201971219300402 NA
10296 rHEV Hepatitis E Hepatitic Hepatitis E virus double stranded DNA Recombinant viral vector Phase 2 GlaxoSmithKline 2011 USA 18 - 58 years 3 doses at regimen of 0, 1, and 6 months NA Aluminum (alum) Capsid Protein ORF2 NA NA National Institute of Health, Novavax NA NA NA NA https://www.who.int/immunization/sage/meetings/2014/october/4_Hepatitis_E_vaccine_pipeline_final_29_Sept_14.pdf NA
10297 HSV15 Genital Herpes Cutaneous Herpes simplex virus double stranded DNA Subunit vaccine Phase 2 Sanofi Pasteur 2021 USA 18 - 55 years NA Intramuscular NA Wild-type HSV virus components except two proteins UL5 and UL29 NA US FDA National Institute of Allergy and Infectious Diseases NA NA NA NCT04222985 https://www.precisionvaccinations.com/vaccines/herpes-vaccine-candidates https://clinicaltrials.gov/ct2/show/NCT04222985
10298 CHIKV-NoLS Chikungunya fever Exanthous Chikungunya virus positive-sense, single-stranded RNA Live-attenuated Phase 2 NA NA NA NA Single dose Subcutaneous NA N-terminal region of capsid protein NA NA NA NA NA 31921059 NA https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6930866/ NA
10299 MV-CHIK Chikungunya fever Exanthous Chikungunya virus positive-sense, single-stranded RNA Virus like particle Phase 2 NA NA NA NA 0.35 mL single measle vaccine dose, twice injection at day 0 and day 28 Intramuscular NA Measles-vectored CHIKV structural proteins NA NA NA NA NA 31921059 NA https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6930866/ NA
10300 EILV/CHIKV Chikungunya fever Exanthous Chikungunya virus positive-sense, single-stranded RNA Virus like particle Phase 2 NA NA NA NA 8.8 log10 PFU (C57BL/6) or 8.5 log10 PFU (IFN?/?R–/–mice) of live EILV/CHIKV, single injection Subcutaneous NA EILV cDNA clone containing CHIKV structural proteins NA NA NA NA NA 31921059 NA https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6930866/ NA
10301 CHIK-VLP Chikungunya fever Exanthous Chikungunya virus positive-sense, single-stranded RNA Virus like particle Phase 2 NA NA NA NA Single dose Intramuscular NA C-E proteins NA NA NA NA NA 31921059 NA https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6930866/ NA
10302 CHIK-VLP Chikungunya fever Exanthous Chikungunya virus positive-sense, single-stranded RNA Virus like particle Phase 2 NA NA NA NA NA Subcutaneous NA CHIKV structural proteins introduced into yeast expression system NA NA NA NA NA 31921059 NA https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6930866/ NA
10303 MV-CHIK Chikungunya fever Exanthous Chikungunya virus positive-sense, single-stranded RNA Live-attenuated Phase 2 Themis Bioscience 2021 USA 21 - 65 years 2 doses 28 days apart Intramuscular NA NA NA US FDA Walter Reed Army Institute of Research NA NA NA NCT03807843 https://clinicaltrials.gov/ct2/show/NCT03807843 NA
10304 TSI-GSD-218 Chikungunya fever Exanthous Chikungunya virus positive-sense, single-stranded RNA Live-attenuated Phase 2 NA NA NA NA Single dose NA NA NA Attenuation by serial, plaque-to-plaque MRC5 cell passages NA NA NA NA NA NA https://academic.oup.com/jid/article/214/suppl_5/S488/2632628 NA
10305 MV/Schwarz Chikungunya fever Exanthous Chikungunya virus positive-sense, single-stranded RNA Recombinant viral vector Phase 2 NA NA NA NA NA NA NA CHIKV structural proteins NA NA NA NA NA NA NA https://link.springer.com/chapter/10.1007/82_2019_175 NA
10306 CHIK-VLP Chikungunya fever Exanthous Chikungunya virus positive-sense, single-stranded RNA Virus like particle Phase 2 Emergent BioSolutions 2020 USA 18 - 45 years 2 doses on day 0, 29 Parenteral or mucosal route Alhydrogel CHIKV structural proteins (C, E3, E2, 6K, E1) NA US FDA National Institute of Health, PaxVax NA NA NA NCT03483961 https://journals.plos.org/plosntds/article?id=10.1371/journal.pntd.0006919 https://clinicaltrials.gov/ct2/show/NCT03483961
10307 MV-CHIKV Chikungunya fever Exanthous Chikungunya virus positive-sense, single-stranded RNA Live-attenuated Phase 2 Institut Pasteur of Shanghai, Themis Bioscience 2021 NA 18 - 55 years 3 doses on day 0, 28 and 196 Intramuscular NA NA NA NA NA NA NA NA NCT02861586 https://journals.plos.org/plosntds/article?id=10.1371/journal.pntd.0006919 https://clinicaltrials.gov/ct2/show/NCT02861586
10308 MVA-mBN85B Measles Exanthous Morbillivirus negative-sense, single-stranded RNA Recombinant viral vector Phase 2 Bavarian Nordic 2012 South Africa 6 months - 6 years 2 doses 4 weeks apart Subcutaneous NA Attenuated Modified Vaccinia Virus Ankara, strain encoding hemagglutinin protein, fusion protein and nucleoprotein of measles virus NA NA NA NA Rouvax NA NCT00891007 https://clinicaltrials.gov/ct2/show/NCT00891007?recrs=abde&cond=measles+vaccines&phase=123&draw=2&rank=3 NA
10309 MeMuRu-OKA Measles, Mumps, Rubella, Varicella Exanthous Morbillivirus, Mumps virus, Rubella virus, Varicella-zoster virus negative-sense, single-stranded RNA Live-attenuated Phase 2 GlaxoSmithKline 2016 Canada 15 months - 6 years NA Subcutaneous NA Jeryl Lynn strain, Schwarz strain, RA 27/3 strain, OKA strain NA NA NA NA NA NA NCT00352898 https://clinicaltrials.gov/ct2/show/NCT00352898 https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-006065-14/DE
10310 HIL-214 (Hillivax) Norovirus Infection Gastrointestinal Norovirus positive-sense, single-stranded RNA Virus like particle Phase 2 Takeda Pharmaceutical Company Limited 2012 USA 18 - 49 years 2 doses 28 days apart Intramuscular MPL, aluminium hydroxide GI.1 Norwalk VLP and GII.4 cVLP NA NA Frazier Healthcare Partners NA NA NA NCT01609257 https://clinicaltrials.gov/ct2/show/NCT01609257 NA
10311 Norovirus GI.1/GII.4 Bivalent VLP vaccine Norovirus Infection Gastrointestinal Norovirus positive-sense, single-stranded RNA Virus like particle Phase 2 Baylor College of Medicine 2014 USA 18 - 49 years NA Intramuscular MPL, Alum GI.1 and GII.4 consensus VLP Baculovirus expressed noroviruses VLPs NA NA NA NA NA NCT02142504 https://www.cdc.gov/norovirus/downloads/global-burden-report.pdf https://clinicaltrials.gov/ct2/show/NCT02142504
10312 RV3-BB Rotavirus Infection Gastrointestinal Rotavirus double stranded RNA Live-attenuated Phase 2 PT Biofarma NA Indonesia 0 - 5 days 3 doses regimen child schedule (0 to 5 days, 8 weeks, and 14 weeks of age or an infant schedule (8 weeks, 14 weeks, and 18 weeks of age) Oral NA Three VP8 subunit proteins expressing P[4], P[6] and P[8] serotypes NA NA NA NA NA NA NA https://preventrotavirus.org/wp-content/uploads/2019/05/ROTA-Brief2-ProductLandscape-SP-1-3.pdf NA